One-On-One: Linnea Duff & Anna Farago

In December 2013, cancer patient and advocate Linnea Duff joined thoracic oncologist and Koch Institute postdoctoral researcher Anna Farago in an intimate conversation about the powerful impact cancer research can have in patients' lives, and how the possibility of having such impact drives the passion and commitment of researchers and staff working at the KI and other cancer research institutions. Watch the recording of this special event to learn more about Linnea's journey and how, after the progression of her lung cancer to stage IV disease in 2008, her treatment and her experience as a patient took a remarkable turn when she enrolled in a clinical trial for a novel ALK inhibitor, the now FDA-approved crizotinib.